Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cel symbols : AZNCF save search
Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -2.09%
H: 5.03%
C: 0.85%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 1.01%
H: 0.81%
C: -0.06%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
drug cel lung cancer cancer drug cancer growth
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
Injectable Drug Delivery Devices Market size to increase by USD 22.29 Bn | Rising prevalence of chronic diseases to accelerate growth | Technavio
Published: 2022-02-22 (Crawled : 04:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 1.71%
H: 2.6%
C: 0.25%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -1.02%
H: 1.2%
C: -0.07%
BAX | $40.93 -0.22% 0.0% 2.2M
|
Health Technology
|
| O: 0.18%
H: 2.74%
C: 2.38%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.26%
H: 0.81%
C: 0.46%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 3.24%
H: 0.18%
C: -1.6%
drug device liver disease cel growth drug delivery
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.